News Veru Inc.

Equities

VERU

US92536C1036

Real-time Estimate Cboe BZX Other stock markets 10:16:40 2024-04-29 am EDT			5-day change	1st Jan Change
1.205 ^USD	-5.12%		-6.69%	+64.58%

Apr. 15	Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	MT
Apr. 01	Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11	Apr. 25	AQ
Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	Apr. 15	MT
Veru Announces Date of 2024 Annual Meeting of Shareholders	Apr. 01	AQ
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Apr. 01	CI
Raymond James Starts Very With Outperform Rating, $3 Price Target	Mar. 28	MT
Veru Reschedules Annual Meeting of Shareholders	Mar. 25	AQ
Veru Reschedules Annual Meeting of Shareholders	Mar. 22	AQ
Certain Options of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Certain Common Stock of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss	Mar. 12	AQ
Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board	Mar. 12	CI
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q	Feb. 27	AQ
Healthcare Innovations and Collaborations Fuel Industry Expansion Stocks Under $1 Look Now! OCGN, VTAK, RSCI, VERU, AGEN	Feb. 21	AQ
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss	Feb. 20	AQ
Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss	Feb. 20	CI
Transcript : Veru Inc., Q1 2024 Earnings Call, Feb 08, 2024	Feb. 08
Veru Reports Fiscal 2024 First Quarter Financial Highlights	Feb. 08	AQ
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs	Feb. 06	AQ
Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study	Feb. 06	CI
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Jan. 31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Veru Inc.

Equities

VERU

US92536C1036

Summary

Filters